Briefing.com

Johnson & Johnson delivered a strong Q2, raised FY26 EPS and revenue guidance, and remains on track to surpass $100 bln in annual revenue for the first time. Innovative Medicine remains the growth engine, while MedTech and Abiomed are the main watch items. See the full analysis: https://www.briefing.com/story-stocks/archive/2026/7/15/johnson--and--johnson-reports-healthy-q2-but-medtech-a-bit-soft?utm_campaign=storystocks&utm_medium=social&utm_source=fb&utm_content=link

After a strong Q1 reporting period, investors will be watching whether Q2 results, margins, and guidance are strong enough to justify the expectations already reflected in stock prices.

For 34 years, Briefing.com has helped investors look beyond the headline numbers and understand what earnings reports mean for stocks, sectors, and the broader market.

Get 50% off Briefing Investor: https://briefing.com/premium-services?utm_source=social&utm_medium=fb&utm_campaign=Q326_Earnings&utm_content=earnings_season

Taiwan Semiconductor's June sales reinforce strong AI and advanced-node demand, but expectations are already high. The next test is whether management can pair Q2 revenue strength with durable margins, a constructive Q3 guide, and evidence that CoWoS capacity is expanding fast enough. Read the full analysis: https://briefing.com/story-stocks/archive/2026/7/13/taiwan-semi-manufacturing-slips-despite-strong-june-sales-as-chip-sector-derisks-(tsm)?utm_campaign=storystocks&utm_medium=social&utm_source=fb&utm_content=link